子宫内膜癌（endometrialcarcinoma, EC）是全球第6大最常见癌症，同时也是美国第二大常见癌症，预计到2023年，美国将有66 200例新发病例。在中国，2022年约有新发病例77 700例，死亡病例13 ...

Bristol Myers Squibb’s Opdivo plus Yervoy gets US FDA nod to treat adult and pediatric patients with mismatch repair deficient colorectal cancer: Princeton, N.J. Thursday, April ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

A global none governmental organisation MSI Nigeria reproductive choices, on Tuesday held one day workshop at Azbir arena in Birnin Kebbi to disseminate information on family planning, reproductive ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...